Case number 2019-1749
Immunex Corporation v. Sanofi-Aventis U.S. LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | IMMUNEX CORPORATION v. SANOFI-AVENTIS U.S. LLC [OPINION] [precedential] (0) |
| Mar 17, 2021 | 90 | Petition for writ of certiorari filed on 03/11/2021 in the U.S. Supreme Court. No.: 20-1285, Immunex Corporation v. Sanofi-Aventis U.S. LLC. [763053] [JCP] [Entered: 03/17/2021 04:14 PM] (0) |
| Dec 4, 2020 | 89 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [740255] [19-1749, 19-1777] [JAB] [Entered: 12/04/2020 10:37 AM] (0) |
| Oct 13, 2020 | 87 | OPINION filed for the court by Prost, Chief Judge; Reyna, Circuit Judge and Taranto, Circuit Judge. Precedential Opinion. [728097] [19-1749, 19-1777] [MJL] [Entered: 10/13/2020 09:44 AM] (0) |
| Oct 13, 2020 | 88 | JUDGMENT. AFFIRMED-IN-PART, DISMISSED-IN-PART. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [728099] [19-1749, 19-1777] [MJL] [Entered: 10/13/2020 09:45 AM] (0) |
| Aug 5, 2020 | 86 | Submitted after ORAL ARGUMENT by Eldora Ellison for Immunex Corporation, Lauren Fornarotto for Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC and Frances Lynch for Andrei Iancu. Panel: Judge: Prost , Judge: Reyna , Judge: Taranto. [712702] [JAB] [Entered: 08/05/2020 12:48 PM] (0) |
| Jul 21, 2020 | 85 | Clerk's letter to Appellant Immunex Corporation, Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC and Intervenor Andrei Iancu regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [709006]--[Edited 07/21/2020 by PBC to upload correct letter] [JAB] [Entered: 07/21/2020 03:11 PM] (0) |
| Jul 15, 2020 | 83 | Amended Certificate of Interest for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 07/15/2020 by email. [707788] [19-1749] [John Garvish] [Entered: 07/15/2020 02:23 PM] (0) |
| Jul 15, 2020 | 84 | Response to notice of oral argument from the Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 07/15/2020 by email. [707791] [19-1749] [Lauren Fornarotto] [Entered: 07/15/2020 02:25 PM] (0) |
| Jul 14, 2020 | 82 | Corrected Response to notice of oral argument from the Appellant Immunex Corporation. Service: 07/14/2020 by email. [707399] [19-1749] [Eldora Ellison] [Entered: 07/14/2020 02:00 PM] (0) |
| Jul 14, 2020 | 81 | Response to notice of oral argument from the Intervenor Andrei Iancu. Service: 07/14/2020 by email. [707343] [19-1749] [Frances Lynch] [Entered: 07/14/2020 11:51 AM] (0) |
| Jul 14, 2020 | 80 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Immunex Corporation, Response to Notice of Oral Argument [79], is not in compliance with the rules of this court (see attached). Compliant document due on 07/21/2020. Service as of this date by the Clerk of Court. [707324] [JAB] [Entered: 07/14/2020 10:59 AM] (1) |
| Jul 14, 2020 | 79 | Response to notice of oral argument from the Appellant Immunex Corporation. Service: 07/14/2020 by email. [707302] [19-1749] This document is non-compliant. See Doc. No. [80]. [Eldora Ellison] [Entered: 07/14/2020 10:20 AM] (2) |
| Jun 22, 2020 | 78 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2008E. Case scheduled August 5, 2020. Response to Notice of Oral Argument due: 07/15/2020. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [702763] [JAB] [Entered: 06/22/2020 01:50 PM] (1) |
| May 6, 2020 | 74 | 6 paper copies of the Corrected Confidential Joint Appendix (Vol. I - III) [71] received from Appellant Immunex Corporation and Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. [692693] [CJF] [Entered: 05/07/2020 08:00 AM] (0) |
| May 1, 2020 | 77 | 6 paper copies of the Opening Brief [23] and Response and Reply Brief [35] received from Appellant Immunex Corporation. [693158] [PBC] [Entered: 05/08/2020 12:18 PM] (0) |
| May 1, 2020 | 76 | 6 paper copies of the Intervenor Brief [48] received from Intervenor Iancu. [693019] [MJL] [Entered: 05/08/2020 09:06 AM] (0) |
| May 1, 2020 | 75 | 6 paper copies of the Confidential Reply Brief [50] received from Genzyme Corporation, Regeneron Pharmaceuticals, Inc., et al. [693017] [MJL] [Entered: 05/08/2020 09:02 AM] (0) |
| Apr 30, 2020 | 72 | RESPONSE of Intervenor Andrei Iancu to the supplemental authority [66] filed by Appellant Immunex Corporation. Service: 04/30/2020 by email. [691325] [19-1749] [Frances Lynch] [Entered: 04/30/2020 02:24 PM] (3) |
| Apr 30, 2020 | 71 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Appellant Immunex Corporation, Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, and Intervenor Andrei Iancu. Number of Pages: 1883. Service: 04/30/2020 by email. [691308]--[Edited 05/01/2020 by JAL - Compliance review complete] [Jon Wright] [Entered: 04/30/2020 01:56 PM] (0) |
| Apr 30, 2020 | 70 | Notice of Correction to Doc No. [56] for Appellant Immunex Corporation. Service: 04/30/2020 by email. [691302] [19-1749] [Jon Wright] [Entered: 04/30/2020 01:48 PM] (6) |
| Apr 29, 2020 | 73 | 6 paper copies of the Corrected Confidential Opening Response Brief [33] received from Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. [692044] [CJF] [Entered: 05/04/2020 03:44 PM] (0) |
| Apr 27, 2020 | 69 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before May 11, 2020. See Administrative Order No. 20-01 (Mar. 20, 2020). [690055] [JAL] [Entered: 04/27/2020 10:25 AM] (0) |
| Apr 20, 2020 | 68 | ORDER filed denying [59] motion filed by Immunex Corporation. Service as of this date by the Clerk of Court. [688439] [LMS] [Entered: 04/20/2020 04:48 PM] (2) |
| Apr 16, 2020 | 67 | RESPONSE of Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC to the supplemental authority [66] filed by Appellant Immunex Corporation. Service: 04/16/2020 by email. [687651] [19-1749] [John Garvish] [Entered: 04/16/2020 04:30 PM] (3) |
| Apr 10, 2020 | 66 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Immunex Corporation. Service: 04/10/2020 by email. [686139] [19-1749] [Eldora Ellison] [Entered: 04/10/2020 05:20 PM] (3) |
| Mar 27, 2020 | 65 | RESPONSE of Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC to the motion [59] filed by Appellant Immunex Corporation. Service: 03/27/2020 by email. [682494] [19-1749] [John Garvish] [Entered: 03/27/2020 04:23 PM] (9) |
| Mar 27, 2020 | 64 | The following conflict dates submitted by Lauren Fornarotto for Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC have been accepted by the court: 08/31/2020, 09/01/2020, 09/02/2020, 09/03/2020, 09/04/2020. [682326] [JAB] [Entered: 03/27/2020 12:11 PM] (0) |
| Mar 27, 2020 | 63 | Notice from Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC regarding conflicts with oral argument. Service: 03/27/2020 by email. [682316] [19-1749] [Lauren Fornarotto] [Entered: 03/27/2020 11:55 AM] (3) |
| Mar 26, 2020 | 62 | The following conflict dates submitted by Eldora Ellison for Immunex Corporation have been accepted by the court: 07/06/2020, 07/07/2020, 07/08/2020, 07/09/2020, 07/10/2020. [682141] [JAB] [Entered: 03/26/2020 03:42 PM] (0) |
| Mar 26, 2020 | 61 | Notice from Appellant Immunex Corporation regarding conflicts with oral argument. Service: 03/26/2020 by email. [682125] [19-1749] [Eldora Ellison] [Entered: 03/26/2020 03:23 PM] (4) |
| Mar 26, 2020 | 60 | Notice from Intervenor Iancu regarding conflicts with oral argument. None. Service: 03/26/2020 by email. [681979] [19-1749] [Frances Lynch] [Entered: 03/26/2020 11:52 AM] (0) |
| Mar 25, 2020 | 59 | MOTION of Appellant Immunex Corporation leave to file a supplemental brief [Consent: opposed]. Service: 03/25/2020 by email. [681578] [19-1749] [Jon Wright] [Entered: 03/25/2020 09:49 AM] (23) |
| Mar 23, 2020 | 58 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [680975] [JAL] [Entered: 03/23/2020 01:56 PM] (1) |
| Mar 18, 2020 | 57 | MODIFIED ENTRY: CORRECTED JOINT APPENDIX FILED for Appellant Immunex Corporation, Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, and Intervenor Iancu. Number of Pages: 1861. Service: 03/18/2020 by email. [680089] --[Edited 03/19/2020 by JAL - Compliance review complete] [Jon Wright] [Entered: 03/18/2020 07:35 PM] (1861) |
| Mar 18, 2020 | 56 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Appellant Immunex Corporation, Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, and Intervenor Iancu. Number of Pages: 1883. Service: 03/18/2020 by email. [680088]--[Edited 03/19/2020 by JAL - Compliance review complete] This document has been corrected. See Doc No.[71] [Jon Wright] [Entered: 03/18/2020 07:28 PM] (0) |
| Mar 11, 2020 | 55 | NOTICE OF NON-COMPLIANCE: The submissions of Appellant Immunex Corporation, Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC, and Intervenor Iancu, Confidential Appendix and Appendix [53], [54], are not in compliance with the rules of this court (see attached). Compliant documents are due on 03/18/2020. Service as of this date by the Clerk of Court. [677846] [JAL] [Entered: 03/11/2020 12:19 PM] (2) |
| Mar 3, 2020 | 54 | FILED from Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC, Intervenor Iancu and Appellant Immunex Corporation. Title: APPENDIX. Service: 03/03/2020 by email. [676031] [19-1749] This document is non-compliant. See Doc No.[55] [Jon Wright] [Entered: 03/03/2020 08:08 PM] (1850) |
| Mar 3, 2020 | 53 | FILED from Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC, Intervenor Iancu and Appellant Immunex Corporation. Title: CONFIDENTIAL APPENDIX. Service: 03/03/2020 by email. [676029] [19-1749] This document is non-compliant. See Doc No.[55] [Jon Wright] [Entered: 03/03/2020 08:02 PM] (0) |
| Mar 3, 2020 | 52 | Joint Statement of Compliance with Fed. Cir. R. 33 for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC and Appellant Immunex Corporation. Service: 03/03/2020 by email. [676015] [19-1749] [John Garvish] [Entered: 03/03/2020 06:29 PM] (3) |
| Mar 3, 2020 | 51 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 03/02/2020 by email. [676013] [19-1749] [John Garvish] [Entered: 03/03/2020 06:10 PM] (3) |
| Feb 25, 2020 | 50 | MODIFIED ENTRY: CONFIDENTIAL REPLY BRIEF FILED for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC. Number of Pages: 17. Service: 02/25/2020 by email. [674212]--[Edited 03/10/2020 by JAL - Compliance review complete] [John Garvish] [Entered: 02/25/2020 06:48 PM] (0) |
| Feb 25, 2020 | 49 | MODIFIED ENTRY: REPLY BRIEF FILED for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC. Number of Pages: 17. Service: 02/25/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [674211] --[Edited 03/10/2020 by JAL - Compliance review complete] [John Garvish] [Entered: 02/25/2020 06:47 PM] (28) |
| Feb 25, 2020 | 48 | MODIFIED ENTRY: INTERVENOR BRIEF FILED for Intervenor Iancu. Number of Pages: 13. Service: 02/25/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [674198] --[Edited 03/10/2020 by JAL - Compliance review complete] [Frances Lynch] [Entered: 02/25/2020 05:39 PM] (20) |
| Feb 25, 2020 | 47 | Entry of appearance for Sarah E. Craven as of counsel for Intervenor Iancu. Service: 02/25/2020 by email. [674009] [19-1749] [Sarah Craven] [Entered: 02/25/2020 12:43 PM] (1) |
| Jan 21, 2020 | 46 | Docketing Statement for the Intervenor Iancu. Service: 01/21/2020 by email. [664836] [19-1749] [Frances Lynch] [Entered: 01/21/2020 04:24 PM] (3) |
| Jan 16, 2020 | 45 | ORDER The revised official caption is reflected above. The intervenor's brief and the cross-appellants' reply brief are due no later than 40 days from the date of filing of this order. Service as of this date by the Clerk of Court. [663816] [LMS] [Entered: 01/16/2020 01:29 PM] (2) |
| Dec 20, 2019 | 42 | Entry of appearance for Frances M. Lynch as principal counsel for U.S. Patent and Trademark Office. Service: 12/20/2019 by email. [658351] [19-1749] [Frances Lynch] [Entered: 12/20/2019 05:53 PM] (1) |
| Dec 20, 2019 | 43 | Entry of appearance for Farheena Y. Rasheed as of counsel for U.S. Patent and Trademark Office. Service: 12/20/2019 by email. [658352] [19-1749] [Farheena Rasheed] [Entered: 12/20/2019 05:55 PM] (1) |
| Dec 20, 2019 | 44 | Entry of appearance for Thomas W. Krause as of counsel for U.S. Patent and Trademark Office. Service: 12/20/2019 by email. [658353] [19-1749] [Thomas Krause] [Entered: 12/20/2019 05:58 PM] (1) |
| Dec 20, 2019 | 41 | Notice of Intervention pursuant to the provisions of 35 USC Section 143 from the Director of the United States Patent and Trademark Office. Service: 12/20/2019 by email. [658350] [19-1749] [Frances Lynch] [Entered: 12/20/2019 05:51 PM] (3) |
| Nov 26, 2019 | 40 | ORDER Notice of Immunex's constitutional challenge [39] is hereby certified to the Attorney General. Within 30 days, the United States is directed to inform the court whether it intends to intervene. The briefing schedule is stayed. Service as of this date by the Clerk of Court. [652547] [LMS] [Entered: 11/26/2019 02:19 PM] (2) |
| Nov 18, 2019 | 39 | Notice from Appellant Immunex Corporation Rule 44(a) Notification. Service: 11/18/2019 by email. [650197] [19-1749] [Jon Wright] [Entered: 11/18/2019 02:53 PM] (3) |
| Nov 14, 2019 | 38 | **TEXT ONLY** ORDER granting motion to extend time to file Cross-Appellants' reply brief [36] filed by Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. The reply brief is due 12/11/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [649430] [TAM] [Entered: 11/14/2019 03:32 PM] (0) |
| Nov 13, 2019 | 37 | Amended Entry of appearance for Lauren L. Fornarotto as of counsel for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 11/13/2019 by email. [649083] [19-1749] [Lauren Fornarotto] [Entered: 11/13/2019 04:12 PM] (2) |
| Nov 12, 2019 | 36 | MOTION of Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC to extend the time to 12/11/2019 to file the Cross-Appellants' Reply Brief. [Consent: unopposed]. Service: 11/12/2019 by email. [648766] [19-1749] [John Garvish] [Entered: 11/12/2019 05:03 PM] (7) |
| Nov 6, 2019 | 35 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellant Immunex Corporation. Number of Pages: 62. Service: 11/06/2019 by email. [647543] --[Edited 12/16/2019 by TAM - compliance review complete] [Jon Wright] [Entered: 11/06/2019 07:12 PM] (75) |
| Nov 1, 2019 | 34 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Number of Pages: 75. Service: 11/01/2019 by email. [646488] --[Edited 12/16/2019 by TAM - compliance review complete] [John Garvish] [Entered: 11/01/2019 04:45 PM] (167) |
| Nov 1, 2019 | 33 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Number of Pages: 75. Service: 11/01/2019 by US mail, email. [646487]--[Edited 12/16/2019 by TAM - compliance review complete and to correct docket text] [John Garvish] [Entered: 11/01/2019 04:42 PM] (0) |
| Oct 25, 2019 | 32 | NOTICE OF NON-COMPLIANCE: The submissions of Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC, Confidential and Non-Confidential Opening and Response Briefs [28], [29], are not in compliance with the rules of this court (see attached). Compliant documents are due on 11/01/2019. Service as of this date by the Clerk of Court. [644664] [JAL] [Entered: 10/25/2019 09:51 AM] (2) |
| Oct 17, 2019 | 31 | **TEXT ONLY** ORDER granting motion to extend time to file Appellant's response and reply brief [30] filed by Appellant Immunex Corporation. The reply brief is due 11/06/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [642815] [TAM] [Entered: 10/17/2019 11:03 AM] (0) |
| Oct 16, 2019 | 30 | MOTION of Appellant Immunex Corporation to extend the time to 11/06/2019 to file the Response and Reply Brief. [Consent: unopposed]. Service: 10/16/2019 by email. [642710] [19-1749] [Jon Wright] [Entered: 10/16/2019 04:47 PM] (7) |
| Sep 17, 2019 | 29 | FILED from Cross-Appellants Sanofi-Aventis U.S. LLC, Genzyme Corporation and Regeneron Pharmaceuticals, Inc. Title: OPENING BRIEF. Service: 09/17/2019 by email. [636216] [19-1749] This document is non-compliant. See Doc No.[32] [John Garvish] [Entered: 09/17/2019 05:21 PM] (166) |
| Sep 17, 2019 | 28 | FILED from Cross-Appellants Sanofi-Aventis U.S. LLC, Genzyme Corporation and Regeneron Pharmaceuticals, Inc. Title: CONFIDENTIAL OPENING BRIEF. Service: 09/17/2019 by email. [636215] [19-1749] This document is non-compliant. See Doc No.[32] [John Garvish] [Entered: 09/17/2019 05:17 PM] (0) |
| Aug 7, 2019 | 27 | **TEXT ONLY** ORDER granting motion to extend time to file Cross-Appellants' principal and response brief [26] filed by Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Brief is due 09/17/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [626546] [TAM] [Entered: 08/07/2019 08:26 AM] (0) |
| Aug 6, 2019 | 26 | MOTION of Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC to extend the time to 09/17/2019 to file the Appellants' Principal and Response Brief. [Consent: unopposed]. Service: 08/06/2019 by email. [626484] [19-1749] [John Garvish] [Entered: 08/06/2019 05:55 PM] (8) |
| Aug 6, 2019 | 25 | Entry of appearance for Matthew T. Cameron as of counsel for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 08/06/2019 by email. [626481] [19-1749] [Matthew Cameron] [Entered: 08/06/2019 05:42 PM] (2) |
| Aug 6, 2019 | 24 | Entry of appearance for Geoffrey L. Smith as of counsel for Cross-Appellants Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 08/06/2019 by email. [626476] [19-1749] [Geoffrey Smith] [Entered: 08/06/2019 05:32 PM] (2) |
| Jul 25, 2019 | 23 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellant Immunex Corporation. Number of Pages: 65. Service: 07/25/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [623622] --[Edited 08/12/2019 by TAM - compliance review complete] [Jon Wright] [Entered: 07/25/2019 05:58 PM] (156) |
| Jul 10, 2019 | 22 | Note to file: The following cases are associated:19-1749 (Lead) with 19-1777 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [620045] [19-1749, 19-1777] [TAM] [Entered: 07/10/2019 11:54 AM] (0) |
| Jul 10, 2019 | 21 | ORDER consolidating appeals (19-1749 with 19-1777). Service as of this date by the Clerk of Court. [620040] [19-1749, 19-1777] [TAM] [Entered: 07/10/2019 11:46 AM] (2) |
| Jul 2, 2019 | 20 | Entry of appearance for Noah S. Frank as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 07/02/2019 by email. [618668] [19-1749] [Nathan Mammen] [Entered: 07/02/2019 03:47 PM] (2) |
| Jul 2, 2019 | 19 | Entry of appearance for Nathan S. Mammen as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 07/02/2019 by email. [618666] [19-1749] [Nathan Mammen] [Entered: 07/02/2019 03:45 PM] (2) |
| Jul 1, 2019 | 18 | **TEXT ONLY** ORDER granting motion to extend time to file brief [17] filed by Appellant Immunex Corporation. Appellant's brief is due 07/25/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [618094] [MMA] [Entered: 07/01/2019 10:54 AM] (0) |
| Jun 28, 2019 | 17 | MOTION of Appellant Immunex Corporation to extend the time to 07/25/2019 to file the Opening Brief. [Consent: unopposed]. Service: 06/28/2019 by email. [617902] [19-1749] [Jon Wright] [Entered: 06/28/2019 04:27 PM] (7) |
| May 17, 2019 | 16 | Certified list from the United States Patent and Trademark Office. Service: 05/16/2019 by email. Appellant's brief is due 07/15/2019. [608155] [MMA] [Entered: 05/17/2019 11:39 AM] (44) |
| Apr 24, 2019 | 15 | Entry of appearance for Eric S. Hansen as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602776] [19-1749] [Eric Hansen] [Entered: 04/24/2019 05:52 PM] (2) |
| Apr 24, 2019 | 14 | Entry of appearance for Joel L. Thollander as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602775] [19-1749] [Joel Thollander] [Entered: 04/24/2019 05:51 PM] (2) |
| Apr 24, 2019 | 13 | Entry of appearance for Lauren L. Fornarotto as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602774] [19-1749] [Lauren Fornarotto] [Entered: 04/24/2019 05:49 PM] (2) |
| Apr 24, 2019 | 12 | Entry of appearance for Mike McKool as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602772] [19-1749] [Mike McKool] [Entered: 04/24/2019 05:46 PM] (2) |
| Apr 24, 2019 | 11 | Entry of appearance for George W. Hicks, Jr. as of counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602763] [19-1749] [George Hicks] [Entered: 04/24/2019 05:09 PM] (2) |
| Apr 24, 2019 | 10 | Docketing Statement for the Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602758] [19-1749] [John Garvish] [Entered: 04/24/2019 05:00 PM] (4) |
| Apr 24, 2019 | 9 | Certificate of Interest for the Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602757] [19-1749] [John Garvish] [Entered: 04/24/2019 04:58 PM] (4) |
| Apr 24, 2019 | 8 | Entry of appearance for John F. Garvish, II as principal counsel for Appellees Genzyme Corporation, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. Service: 04/24/2019 by email. [602756] [19-1749] [John Garvish] [Entered: 04/24/2019 04:57 PM] (2) |
| Apr 24, 2019 | 7 | Docketing Statement for the Appellant Immunex Corporation. Service: 04/24/2019 by email. [602710] [19-1749] [Eldora Ellison] [Entered: 04/24/2019 03:47 PM] (4) |
| Apr 24, 2019 | 6 | Certificate of Interest for the Appellant Immunex Corporation. Service: 04/24/2019 by email. [602708] [19-1749] [Eldora Ellison] [Entered: 04/24/2019 03:45 PM] (3) |
| Apr 24, 2019 | 5 | Entry of appearance for David W. Roadcap as of counsel for Appellant Immunex Corporation. Service: 04/24/2019 by email. [602706] [19-1749] [David Roadcap] [Entered: 04/24/2019 03:42 PM] (2) |
| Apr 24, 2019 | 4 | Entry of appearance for David H. Holman as of counsel for Appellant Immunex Corporation. Service: 04/24/2019 by email. [602702] [19-1749] [David Holman] [Entered: 04/24/2019 03:40 PM] (2) |
| Apr 24, 2019 | 3 | Entry of appearance for Jon E. Wright as of counsel for Appellant Immunex Corporation. Service: 04/24/2019 by email. [602699] [19-1749] [Jon Wright] [Entered: 04/24/2019 03:38 PM] (2) |
| Apr 24, 2019 | 2 | Entry of appearance for Eldora L. Ellison as principal counsel for Appellant Immunex Corporation. Service: 04/24/2019 by email. [602695] [19-1749] [Eldora Ellison] [Entered: 04/24/2019 03:36 PM] (2) |
| Apr 10, 2019 | 1 | Appeal docketed. Received: 04/08/2019. [598962] Entry of Appearance due 04/24/2019. Certificate of Interest is due on 04/24/2019. Docketing Statement due 04/24/2019. Certified List due on 05/20/2019. [MMA] [Entered: 04/10/2019 12:25 PM] (41) |
